Jennifer Marvin-Peek, MD

Peer-Reviewed Articles

1. Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Zucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carre M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol:JCO2600347, 2026. e-Pub 2026. PMID: 42391582.
2. Marvin-Peek J, DiNardo CD, Loghavi S, Ravandi F, Borthakur G, Daver NG, Kadia TM, Jabbour E, Dunbar A, Tang G, Short NJ, Haddad FG, Abbas HA, Kugler E, Maiti A, Issa GC, Takahashi K, Bhalla K, Pemmaraju N, Alvarado Y, Shpall EJ, Popat U, Ramdial J, Champlin RE, Kantarjian HM, Garcia-Manero G, Senapati J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer e70434, 2026. e-Pub 2026. PMID: 42089433.
3. Marvin-Peek J, Kantarjian H, Jen W, Daver N, Short N, Borthakur G, Bazinet A, Maiti A, Abbas H, Yilmaz M, Issa G, Macfarland M, Alvarado Y, Garcia-Manero G, Alousi A, Popat U, Shpall E, Ravandi F, DiNardo C, Kadia TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. AJH, 2026. e-Pub 2026. PMID: 41781030.
4. Senapati J, Croden J, Garcia-Manero G, Takahashi K, Daver NG, Kadia TM, Borthakur G, Short NJ, Jabbour E, Haddad F, Marvin-Peek J, Abbas HA, Bose P, Tang G, Loghavi S, Shpall EJ, Ramdial J, Popat UR, Champlin RE, Ravandi F, Kantarjian HM, Dinardo CD. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. HemaSphere 10:e70317, 2026. e-Pub 2026. PMID: 41694734.
5. Turkalj S, Radtke F, Stoilova B, Rabea, Mecklenbrauck, Groom A, Jakobsen N, Lachowiez C, Metzner M, Batchimeg, Usukhbayar, Salazar M, Zeng Z, Sanam, Loghavi, Marvin-Peek J, Körber V, Ravandi F, Issa G, Kadia T, Vasiliki, Symeonidou, Groot AD, Kantarjian H, Takahashi K, Konopleva M, Courtney, DiNardo, Vyas AP. Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy. Blood, 2025. e-Pub 2025. PMID: 41191518.
6. Hill J, Marvin-Peek J, Sasaki K, Bresser S, Dabaja BS, Jain N, Borthakur G, Abbas HA. Central nervous system relapse of core-binding factor acute myeloid leukemia. Leuk Lymphoma, 2025. e-Pub 2025. PMID: 40386862.
7. DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen W, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. JCO 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
8. Croden J, Wei-Ying J, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia, 2025. e-Pub 2025. PMID: 40813623.
9. Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo Y, Garza AI, Root JL, Qiao W, Arruda A, Ivo Veletic MD, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes. Blood, 2025. PMID: 40179376.
10. Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Borthakur G, Daver N, Kadia TM, Short, NJ, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and outcomes to contemporary therapies. AJH, 2025. PMID: 39921561.
11. Jen, Wei-Ying, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia, TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McDue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow up of a phase 2 study of all-trans retinoic acid, arsenic trioxide and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662, 2025. e-Pub 2025. PMID: 39584789.
12. Marvin-Peek J, Sasaki K, Kontoyiannis DP, Adachi J, Ohanian M, Takahashi K, Issa GC, Kornblau S, Abbas HA. Nontuberculosis Mycobacteria (NTM) Infections in Patients with Leukemia: A Single Center Case Series. Frontiers Medicine 11(1402897), 2024. e-Pub 2024. PMID: 39149601.
13. Narayanan N, Marvin-Peek J, Abouelnaaj MK, Majid D, Wang B, Brown BD, Qui Y, Kornblau SM, Abbas HA. Reverse Phase Proteomic Array Profiling of Asparaginase Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia. J Proteome Res 23(7):2495-2504, 2024. e-Pub 2024. PMID: 38829961.
14. Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, Hammond D, Swaminathan M, Jain N, Wierda W, Ferrajoli A, DiNardo CD. Effect of Digital Health Coaching on Self-Efficacy and Patient Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematologica, 2024. PMID: 38861934.
15. Marvin-Peek J, Wei-Ying J, Kantarjian H, McCue D, Haddad FG, Weirda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma, 2024. PMID: 38749022.
16. Marvin-Peek J, Mason EF, Kishtagari A, Jayani RV, Dholaria B, Kim TK, Engelhardt BG, Chen H, Strickland S, Savani B, Ferrell B, Kassim A, Savona M, Mohan S, Byrne M. TP53 mutations are associated with increased infections and reduced hematopoietic cell transplantation rates in myelodysplastic syndrome and acute myeloid leukemia. Transplant Cell Ther 390(e1-390):e10, 2023. e-Pub 2023. PMID: 36906277.
17. Marvin-Peek J, Hemnes A, Huang S, Silverman-Loyd L, MacKinnon G, Annis J, Martin SS, Blaha MJ, Brittain EL. Daily steps counts are associated with hospitalization risk in pulmonary arterial hypertension. Am J Respir Crit Care Med 204(11):1338-1340, 2021. e-Pub 2021. PMID: 34375161.
18. Marvin-Peek J, Rhoads J, Major AS. FcgRIIb on CD11c+ cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr-/- mice. Atherosclerosis 285:108-119, 2019. e-Pub 2019. PMID: 31051414.

Review Articles

1. Marvin-Peek J, Loghavi S, Issa GC, Daver NG, Kadia TM, Ravandi F, DiNardo CD. The role of advanced molecular diagnostics in informing targeted therapies for AML. Human Pathology 106179, 2026. e-Pub 2026. PMID: 42219114.
2. Marvin-Peek J, Jen W-Y, Ravandi F. Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatment. Exp Rev of Clin Pharm, 2026. e-Pub 2026. PMID: 41910471.
3. Jen Y, Lachowiez C, Marvin-Peek J, Altman J, Yilmaz M, Garcia J, Abaza Y, Short N, Zeidner J, Daver N, Wei A, Issa G, DiNardo CD. Lower Intensity Triplet Therapy in Acute Myeloid Leukemia: A Practical Guide. Blood Cancer Journal, 2025. e-Pub 2025. PMID: 41290614.
4. Marvin-Peek J, Gilbert JS, Pollyea DA, DiNardo CD. Therapy of AML with Lower Intensity Regimens – Where are we now and where can we go?. Am J Hematol Am J Hematol, 2024. PMID: 39016070.
5. Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers (Basel) 14(3):497, 2022. e-Pub 2022. PMID: 35158765.

Abstracts

1. Marvin-Peek J, Nguyen AH, Campoverde L, Rebboah E, Xiao W, Hachem M, Veletic I, Manshouri T, Braish J, Hajjar GE, Issa G, Pemmaraju N, Masarova L, Bose P, Abbas H. INTEGRATED CLINICAL AND MOLECULAR REGISTRY WITH LONGITUDINAL BIOREPOSITORY IN SYSTEMIC MASTOCYTOSIS: A SINGLE-INSTITUTION COHORT. The European Hematologic Association (EHA) 31st Congress 10(s1):PS2003.
2. Marvin J, Balsamo JA, Rhoads JP, Major AS. FcgRIIb on CD11c+ cells alters liver and adipose tissue inflammation affecting glucose tolerance and atherosclerosis in female mice. Southeastern Immunology.
3. Marvin-Peek J, Huang S, Hemnes A, MacKinnon G, Annis J, Brittain E. Lower daily step counts are associated with increased risk of hospitalization in patients with pulmonary arterial hypertension. ATS.
4. Marvin-Peek J, Mason E, Jayani R, Dholaria B, Kim TK, Engelhardt BG, Chen H, Kassim A, Savona M, Savani B, Strickland S, Mohan S, Byrne M. Factors affect low hematopoietic cell transplantation rates in TP53-mutated MDS/AML and predictors of overall survival. TCT.
5. Marvin-Peek J, Maiti A, Alvarado Y, Daver N, Sasaki K, Borthakur G, Short N, Chien K, Haddad F, Hammond D, Issa G, Jabbour E, Montalban-Bravo G, Jen W, Swaminathan M, Takahashi K, Abbas H, Mullin J, Kornblau S, Pemmaraju N, Ravandi-Kashani F, Senapati J, Yilmaz M, Andreeff M, Ishizawa J, Jain N, Kadia T, Masarova L, Garcia-Manero G, Kantarjian H, DiNardo C. A phase IB/2 trial of an all-oral “triplet” regimen for IDH-mutated myeloid malignancies: decitabine/cedazuridine and venetoclax in combination with ivosidenib/enasidenib. The European Hematology Association (EHA) 30th Congress.
6. Marvin-Peek J, DiNardo CD. IDH Inhibitor Combination Strategies in IDH-Mutated AML. Society of Hematologic Oncology (SOHO) 25:S81-S83.
7. Marvin-Peek J, A Maiti, Y Alvarado, N Daver, K Sasaki, G Borthakur, N Short, K Chien, F Haddad, DE Hammond, GC Issa, E Jabbour, G Montalban Bravo, W-Y Jen, MS Swaminathan, K Takahashi, HA Abbas, J Mullin, S Kornblau, N Pemmaraju, F Ravandi, J Senapati, M Yilmaz, M Andreeff, J Ishizawa, N Jain, T Kadia, L Masarova, G Garcia-Manero, HM Kantarjian, CD DiNardo. AML-150: A Phase 1b/2 Trial of an All-Oral “Triplet” Regimen for IDH-Mutated Myeloid Malignancies: Decitabine or Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib. Society of Hematologic Oncology 25:S404-S405.
8. Marvin-Peek J, Kantarjian HM, Jen WY, Borthaku G, Daver N, Maiti A, Short NJ, Kornblau SM, Pemmaraju N, Kugler E, Bazinet A, Alvarado-Valero Y, Abbas HA, Garcia-Manero G, Popat U, Shpall EJ, Ravandi F, DiNardo CD, Kadia TM. Impact of post-remission intensive (IC) consolidation chemotherapy cycles on overall and relapse free survival after allogeneic stem cell transplant (SCT) in patients with acute myeloid leukemia (AML) receiving IC + venetoclax. American Society of Hematology 2024 Annual Conference.
9. Marvin-Peek J, DiNardo CD, Jen WY, Short NJ, Alvarado Valero Y, Borthakur G, Daver N, Kugler E, Bazinet A, Abbas HA, Yillmaz M, Garcia-Manero G, Kantarjian HM, Kadia TM. Less may be more: The impact of post-remission intensive (IC) consolidation chemotherapy cycles on outcomes in newly diagnosed acute myeloid leukemia receiving IC + venetoclax. American Society of Hematology 2024 Annual Conference.
10. Marvin-Peek J, Jen WY, Short NJ, Issa GC, Yilmaz M, Montalban-Bravo G, Bazinet A, Sasaki K, Maiti A, Borthakur G, Hammond D, Chien KS, Abbas HA, Pemmaraju N, Garcia-Manero G, Jabbour E, Ravandi F, Kadia TM, Daver N, DiNardo CD. Treatment intensity in acute myeloid leukemia with extramedullary disease. American Society of Hematology 2024 Annual Conference.
11. Marvin-Peek J, Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, Lachowiez CA, Alvarado Y, Montalban-Bravo G, Sasaki K, Haddad FG, Issa GC, Masarova L, Abbas HA, Andreef M, Borthakur G, Mullin J, Tippet GD, Chien KS, Hammond D, Ishizawa J, Jain N, Reville PK, Swaminathan M, Yilmaz M, Daver N, Kadia TM, Ravandi F, Garcia-Manero G, Kantarjian HM, DiNardo CD. Clinical outcomes using frontline “triplet” regimens for newly diagnosed IDHmutated acute myeloid leukemia (AML): a pooled analysis of two phase Ib/2 clinical trials. American Society of Hematology 2024 Annual Meeting.
12. Marvin-Peek J, Garcia JS, Borthakur G, Garcia-Manero G, Short NJ, Kadia TM, Loghavi S, Masarova L, Daver N, Maiti A, Takahashi K, Sasaki K, Hammond D, Tippet GD, Wilson D, Chien KS, Bose P, Reville PK, Lachowiez CA, Jain AG, Issa GC, Jain N, Montalban-Bravo G, Luskin MR, Carraway HE, Ravandi F, Kantarjian HM, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies: a 2024 update. Annual Society of Hematology 2024 Annual Conference.
13. Marvin-Peek J, Chan O, Ambinder A, Madanat YF, Chin K, Mercurio A, Kennedy V, Kondapally Y, Kadia T, Daver N, Mims A, Oulidi I, Baratam P, Nicolet D, Mrozek K, Walker M, Joshi U, Ali NA, Roberts H, Kehoe T, Jain A, Ormond S, Burkart M, Swoboda D, Mardis E, Smith B, DiNardo C, Pollyea D, Eisfeld A. MOLECULAR PATTERNS AND THERAPY-SPECIFIC SURVIVAL OF PATIENTS (PTS) WITH IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML) WITH RESPECT TO SELF-REPORTED RACE-ETHNICITY. The European Hematology Association (EHA) 31st Congress 10(s1):PS1642.
14. Marvin-Peek J, Li W, Bhagnani T, Vestin A, Angiolillo A, Mackay EK, Kuang Y, Garcia-Manero G, DiNardo C. INDIRECT COMPARISON OF IVOSIDENIB + VENETOCLAX + AZACITIDINE VERSUS DOUBLET REGIMENS IN INTENSIVE CHEMOTHERAPY-INELIGIBLE IDH1-MUTATED ACUTE MYELOID LEUKEMIA. The European Hematology Association (EHA) 31st Congress 10(s1):PF513.
15. Marvin-Peek J, Garcia J, Borthakur G, Short N, Luskin M, Lachowiez C, Kadia T, Maiti A, Masarova L, Daver N, Loghavi S, Takahashi K, Issa G, Traer E, Swords R, Tidwell R, Chen E, Vedula R, Jain A, Montalban-Bravo G, Yilmaz M, Tippett D, Wilson D, Boer L, Chien K, Jain N, Bose P, Ravandi F, Carraway H, Garcia-Manero G, Kantarjian H, DiNardo C. A MULTICENTER PHASE 1B/2 TRIAL OF AZACITIDINE, VENETOCLAX, AND IVOSIDENIB IN IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML). The European Hematology Association (EHA) 31st Congress 10(s1):S127.
16. Marvin-Peek J, Garcia JS, Borthakur G, Short N, Luskin MR, Lachowiez CA, Kadia T, Daver N, Issa GC, Traer E, Swords R, Jain AG, Dylan Wilson MY, Boer L, Ravandi F, Carraway HE, Garcia-Manero G, Kantarjian H, DiNardo CD. A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). 2026 ASCO Annual Meeting 44(suppl 16; abstr 6503).
17. Abbas HA, Wang B, Marvin-Peek J, Yuan B, Garza AI, Root JL, Arruda A, Liu Y, DiNardo CD, Kadia TM, Daver N, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Reville PK. Blood-based proteomic profiling identifies OSMR as a novel biomarker. American Society of Hematology 2024 Annual Conference.
18. Trukalj S, Stoilova B, Groom AJ, Radtke FA, Mecklenbrauck R, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa GC, Kadia TM, Symeonidu V, de Groot A, Kantarjian KM, Takahashi K, Konopleva M, DiNardo, CD, Vyas P. Clonal basis of resistance and response to ivosidenib combination therapies is established early during treatment of IDH1-mutated myeloid malignancies. American Society of Hematology 2024 Annual Conference.

Book Chapters

1. Marvin-Peek J, Swaminathan, M., Naqvi, K, Abbas, HA. What the Intensivist Needs to Know About Leukemia Patients. In: Oncologic Critical Care. 2. Springer Nature, 2026.
2. Dholaria B, Marvin-Peek J, Savani BN. Hematopoietic Cell Transplantation for Hematologic Malignancies. In: Wintrobe’s Clinical Hematology. 15th. Wolters Kluwer, 2023.

Letters to the Editor

1. Marvin-Peek J, DiNardo CD. Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?. Journal of Clinical Oncology, 2026.